JP2017128550A - 細胞老化抑制剤 - Google Patents
細胞老化抑制剤 Download PDFInfo
- Publication number
- JP2017128550A JP2017128550A JP2016010965A JP2016010965A JP2017128550A JP 2017128550 A JP2017128550 A JP 2017128550A JP 2016010965 A JP2016010965 A JP 2016010965A JP 2016010965 A JP2016010965 A JP 2016010965A JP 2017128550 A JP2017128550 A JP 2017128550A
- Authority
- JP
- Japan
- Prior art keywords
- residue
- cell
- glucose
- aging
- anhydrofructose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000032677 cell aging Effects 0.000 title abstract description 38
- 239000003112 inhibitor Substances 0.000 title abstract description 19
- OCLOLUFOLJIQDC-UHFFFAOYSA-N 1,5-AF Natural products OCC1OCC(=O)C(O)C1O OCLOLUFOLJIQDC-UHFFFAOYSA-N 0.000 claims abstract description 49
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims abstract description 25
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 6
- 229930182470 glycoside Natural products 0.000 claims description 6
- 150000002338 glycosides Chemical class 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 125000003563 glycoside group Chemical group 0.000 claims 1
- 230000032683 aging Effects 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 8
- 208000005623 Carcinogenesis Diseases 0.000 abstract description 6
- 230000036952 cancer formation Effects 0.000 abstract description 6
- 231100000504 carcinogenesis Toxicity 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 14
- 238000000034 method Methods 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 7
- 210000003556 vascular endothelial cell Anatomy 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 230000025084 cell cycle arrest Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000009758 senescence Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 108010034791 Heterochromatin Proteins 0.000 description 3
- 108010057455 alpha-1,4-glucan lyase Proteins 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000004458 heterochromatin Anatomy 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 108010034143 Inflammasomes Proteins 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 241000235349 Ascomycota Species 0.000 description 1
- 108091007065 BIRCs Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
(1)1,5-AF及び/又は式:G-(G)n-AF(式中、AFは1,5-AF残基であり、Gはグルコース残基であり、且つnは0〜20の整数であり、但し、前記グルコース残基には側鎖として他のグルコース単位がグリコシド結合していてもよい)で示される化合物を有効成分として含有する細胞老化抑制剤。
(2)1,5-AF及び/又は式:G-(G)n-AF(式中、AFは1,5-AF残基であり、Gはグルコース残基であり、且つnは0〜20の整数であり、但し、前記グルコース残基には側鎖として他のグルコース単位がグリコシド結合していてもよい)で示される化合物を有効成分として含有する老化予防又は治療剤。
(3)1,5-AF及び/又は式:G-(G)n-AF(式中、AFは1,5-AF残基であり、Gはグルコース残基であり、且つnは0〜20の整数であり、但し、前記グルコース残基には側鎖として他のグルコース単位がグリコシド結合していてもよい)で示される化合物を有効成分として含有する発癌予防剤。
1,5-AF又はGAFによる細胞老化抑制の評価を、代表的なSA-βgal誘導法であるH2O2刺激(200μM(3時間刺激)、5日間培養)による培養血管内皮細胞のSA-βgal発現に対する1,5-AF又はGAFの効果の測定と、同時に細胞形態変化の観察により行った。
本実施例で使用した1,5-AFは、純度が90%以上であった。また、本実施例で使用したGAFは、純度が90%以上であった。
結果を図1に示す。図1において、「cont(control)」は、H2O2刺激も1,5-AF又はGAFの添加も行わずに培養した培養血管内皮細胞の結果であり;「H2O2」は、H2O2刺激のみを行い培養した培養血管内皮細胞の結果であり;「H2O2-GAF10(H2O2 GAF 10μg/ml)」は、H2O2刺激後、GAFを添加して培養した培養血管内皮細胞の結果であり;「H2O2-AF10(H2O2AF 10μg/ml)」は、H2O2刺激後、1,5-AFを添加して培養した培養血管内皮細胞の結果である。
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016010965A JP6706852B2 (ja) | 2016-01-22 | 2016-01-22 | 細胞老化抑制剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016010965A JP6706852B2 (ja) | 2016-01-22 | 2016-01-22 | 細胞老化抑制剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017128550A true JP2017128550A (ja) | 2017-07-27 |
JP6706852B2 JP6706852B2 (ja) | 2020-06-10 |
Family
ID=59395364
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016010965A Active JP6706852B2 (ja) | 2016-01-22 | 2016-01-22 | 細胞老化抑制剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6706852B2 (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005154425A (ja) * | 2003-10-28 | 2005-06-16 | Nihon Starch Co Ltd | 抗腫瘍剤 |
JP2014227403A (ja) * | 2013-05-24 | 2014-12-08 | オリザ油化株式会社 | 抗皮膚老化用組成物 |
-
2016
- 2016-01-22 JP JP2016010965A patent/JP6706852B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005154425A (ja) * | 2003-10-28 | 2005-06-16 | Nihon Starch Co Ltd | 抗腫瘍剤 |
JP2014227403A (ja) * | 2013-05-24 | 2014-12-08 | オリザ油化株式会社 | 抗皮膚老化用組成物 |
Non-Patent Citations (3)
Title |
---|
BIOMED RESEARCH INTERNATIONAL, vol. 2014, JPN6019040267, 2014, pages 831841 - 13, ISSN: 0004136147 * |
JOURNAL OF APPLIED GLYCOSCIENCE, vol. 46, no. 4, JPN6019040264, 1999, pages 439 - 444, ISSN: 0004136145 * |
農林水産技術研究ジャーナル, vol. 10, no. 10, JPN6019040265, 1987, pages 5 - 12, ISSN: 0004136146 * |
Also Published As
Publication number | Publication date |
---|---|
JP6706852B2 (ja) | 2020-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI757228B (zh) | 含有槲皮素配糖體之筋萎縮抑制劑 | |
JP5417385B2 (ja) | 脳腫瘍を治療するための医薬組成物又は脳腫瘍細胞のテモゾロミド耐性を低減させるための医薬組成物、及びその使用 | |
JP2001064192A (ja) | ランゲルハンス細胞の遊走抑制剤及び抗原提示抑制剤 | |
CN109517872B (zh) | 红景天苷在保护干细胞活性中的应用 | |
CN113164420A (zh) | 治疗组合物 | |
WO2016159593A2 (ko) | 락토코커스 중앙젠시스를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물 | |
US20180104269A1 (en) | Composition for suppressing muscular fatty change | |
NZ572366A (en) | THE USE OF NICOTINE, ANALOGUES THEREOF, PRECURSORS THEREOF OR DERIVATIVES THEREOF IN THE TREATMENT OF VARIOUS PATHOLOGICAL PROCESSES CAPABLE OF IMPROVEMENT WITH a-MSH ADMINISTERED IN PROPHYLACTIC OR THERAPEUTIC FORM | |
JP4428486B1 (ja) | 線溶賦活剤 | |
KR101594115B1 (ko) | 1,2,4,5-tetramethoxybenzene을 유효성분으로 포함하는 알레르기 질환의 예방 또는 치료용 조성물 | |
KR101514257B1 (ko) | 의약 조성물 및 이를 이용한 약용 화장품 | |
JP6706852B2 (ja) | 細胞老化抑制剤 | |
KR102650558B1 (ko) | 락토바실러스 람노서스 pl60을 유효성분으로 함유하는 염증질환 예방, 개선 또는 치료용 프로바이오틱스 조성물 | |
KR102412352B1 (ko) | ERR-α 억제제를 유효성분으로 하는 백혈병 치료용 약학 조성물 | |
JP7430010B2 (ja) | 幹細胞の機能強化用組成物 | |
KR20190018795A (ko) | 마이크로 RNA-30a 및 RNA-30b를 유효성분으로 함유하는 방사선 치료 민감제 조성물 | |
US20180289656A1 (en) | Compositions and methods to treat urinary tract infections | |
WO2014117056A1 (en) | Therapeutic compounds | |
KR102119795B1 (ko) | 브로콜리 추출물을 포함하는 항염증 조성물 | |
JP4825413B2 (ja) | 抗腫瘍剤 | |
CN103800346A (zh) | 葡萄糖类似物在制备治疗或预防细胞死亡疾病药物中的应用 | |
JP2020100601A (ja) | 一酸化窒素合成酵素活性化剤 | |
KR102642293B1 (ko) | 거문도닥나무 추출물을 포함하는 피부질환 예방 또는 치료용 조성물 | |
Tang et al. | Saikosaponin A ameliorates inflammatory response by modulating P38MAPK pathway in rats with depression and myocardial ischemia | |
KR102015525B1 (ko) | 단백질 키나제 c 저해제를 포함하는 염증성 질환을 치료하기 위한 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190116 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190116 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191016 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191023 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191223 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200210 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200407 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200501 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6706852 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |